

The role of Vaccines in AMR – the European perspective

Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI)



EU One Health Action Plan on AMR

(June 2017)



MAKING THE EU
A BEST
PRACTICE
REGION ON AMR

Including better
prevention and control



BOOSTING
RESEARCH,
DEVELOPMENT
AND
INNOVATION
ON AMR



SHAPING THE
GLOBAL
AGENDA ON
AMR



#EUAMRaction


IMI – Europe's partnership for health

IMI1: 2008-2013


€2 bn budget
59 projects

IMI2: 2014-2020


€3.3 bn budget
More ambitious
More open
Greater scope



- **Antimicrobial resistance**
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- **Vaccines**



New Drugs for Bad Bugs (ND4BB)



IMI ND4BB

Challenges and opportunities

- Pneumococcal conjugate vaccine- children and elderly
- Typhoid vaccine
- Influenza vaccines and prevention of secondary infection
- But how do we deal with nosocomial infections.
 - Who should get these vaccines?
 - Are the vaccines available for the right infectious agent?
 - Would there be a market for companies to invest in?
 - R&D costs would be very high due to complexity and heterogeneity
- Need validated biobanks of nosocomial agents
- Complex regulatory frameworks and reimbursement regimens
- Vaccines for animals- aquaculture proof of concept from Norway


Visit our new website
www.imi.europa.eu

Sign up our newsletter
bit.ly/IMInewsletter

Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)

Join our LinkedIn group
bit.ly/LinkedInIMI

Email us
infodesk@imi.europa.eu



**10 YEARS OF
BREAKTHROUGHS**
A HEALTHIER
FUTURE

